European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Nov 2020
Randomized Controlled TrialPharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial.
Remimazolam is a novel and ultra-short-acting sedative currently developed for intravenous use in procedural sedation, general anesthesia, and ICU sedation. However, intravenous administration is not always appropriate, depending on the patient or setting. This study evaluated intranasal administration as a potential alternative route. ⋯ Intranasal administration of remimazolam was safe and caused sedative effects. However, the severe pain and discomfort caused by intranasal remimazolam prohibit its use by this route of administration, at least with the currently available intravenous formulation.